XORTX Therapeutics Inc.
XRTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.00 | 0.00 | -0.06 |
| FCF Yield | -15.79% | -23.78% | -18.04% | -25.72% |
| EV / EBITDA | -3.84 | -3.49 | -2.55 | 7.12 |
| Quality | ||||
| ROIC | -24.99% | -42.85% | -34.84% | -19.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 1.11 | 0.92 | -7.23 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 23.85% | -26.00% | 27.33% | -14.89% |
| Safety | ||||
| Net Debt / EBITDA | 2.58 | 1.40 | 2.80 | -16.84 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,918.90 | -1,142.12 | -1,229.96 | -297.64 |